e-learning
resources
ERJ
2014
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Can IASLC/ATS/ERS subtype help predict response to chemotherapy in small biopsies of advanced lung adenocarcinoma?
Riely Gregory J., Travis William D.
Source:
Eur Respir J 2014; 43: 1240-1242
Journal Issue:
May
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Riely Gregory J., Travis William D.. Can IASLC/ATS/ERS subtype help predict response to chemotherapy in small biopsies of advanced lung adenocarcinoma?. Eur Respir J 2014; 43: 1240-1242
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Cisplatin/pemetrexed chemotherapy versus palliative care survival in malignant pleural mesothelioma
Lung function assessment in octogenarians with lung cancer diagnosis
Home-based telerehabilitation program using real-time monitoring and interactive exercise for patient with lung cancer: A feasibility study
Related content which might interest you:
TTF-1 for prediction of response to chemotherapy in patients with locally advanced or metastatic small cell lung cancer (SCLC)
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 78s
Year: 2005
Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy
Source: Eur Respir J 2012; 39: 1437-1442
Year: 2012
Contribution of tumor markers to pretreatment staging of operable lung cancer
Source: Eur Respir J 2003; 22: Suppl. 45, 360s
Year: 2003
Influence of histological subtypes of bronchioloalveolar carcinoma on prognosis and treatment
Source: Annual Congress 2006 - Prognostic factors in lung cancer
Year: 2006
Impact of neoadjuvant therapy on tumor resectability and survival of patients with locally advanced non-small cell lung cancer
Source: Annual Congress 2011 - General thoracic surgery II
Year: 2011
Relevance of the novel IASLC/ATS/ERS classification of lung adenocarcinoma in advanced disease
Source: Eur Respir J 2014; 43: 1439-1447
Year: 2014
Should there be a specific management for large cell neuroendocrine carcinoma?
Source: Annual Congress 2005 - Neuroendocrine tumours of the lung
Year: 2005
Neo-adjuvant chemotherapy: level of evidence in early stage and in marginally resectable disease
Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts
Year: 2005
Predictors of radiation-induced lung toxicity in patients with locally advanced non small cell lung cancer (NSCLC): a retrospective analysis
Source: Annual Congress 2009 - Management of thoracic malignancies
Year: 2009
Chemotherapy in advanced non small cell lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 77s
Year: 2005
Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy?
Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies
Year: 2007
Age and stage at presentation in lung cancer
Source: Annual Congress 2005 - Management of lung cancer: clinical problems
Year: 2005
Should the treatment of advanced lepidic adenocarcinoma be adapted to the pathological subtype?
Source: Eur Respir J 2015; 46: 1259-1261
Year: 2015
Stage I-IIIa small cell lung cancer (SCLC): multimodal therapy including surgery
Source: Eur Respir J 2001; 18: Suppl. 33, 318s
Year: 2001
Is there a difference in response to first line chemotherapy related to age in patients with locally advanced or metastatic non-small lung cancer?
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013
Objective measurement of tumor central location can predict nodal involvement in patients with cT1N0M0 non-small cell lung cancer
Source: Virtual Congress 2020 – Screening and early lung cancer
Year: 2020
Treatment of extensive-stage small cell lung carcinoma: current status and future prospects
Source: Eur Respir J 2010; 35: 202-215
Year: 2010
Pulmonary re-biopsy in non–small-cell lung cancer (NSCLC) locally advanced or metastatic with EGFR-T790M resistance.
Source: International Congress 2018 – Bronchoscopy and transthoracic ultrasound
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept